Key Takeaways
  • Compounded peptides are prepared for one patient on a valid prescription. Research use only peptides are sold online with a label saying they are not for human use.
  • On October 28, 2026, HHS said it does not intend to act against compounding BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon when all the policy's conditions are met.
  • This is enforcement discretion, not approval. None of the six is FDA approved, and no final rule has added them to the 503A bulks list.
  • Retatrutide, blends, pre-filled pens and 503B outsourcing facilities stay outside the policy.
  • HHS presents the policy as a way to discourage research use only peptides from foreign manufacturers. It gives those sellers no protection.
  • The policy is temporary and can be revisited if a safety signal or quality issue arises.

What is the difference between compounded and research use only peptides?

A compounded peptide is prepared by a licensed pharmacy or physician for one identified patient, on a valid prescription. A research use only peptide is sold online with a label saying it is not for human use, with no prescription and no clinician involved. Since October 28, 2026, this difference matters more in the United States, because HHS has said it does not intend to act against the first route for six peptides, under strict conditions, while presenting that policy as a way to discourage the second.

Neither route is an FDA approved medicine. HHS states that compounded drugs are not FDA approved, which means FDA does not review their safety, effectiveness or quality before they are marketed. A research use only label offers even less: as we explain in our guide on whether peptides are legal, it is a commercial practice and not a legal category.

Compounded, under the HHS policyResearch use only
Who supplies itState licensed pharmacy, federal facility or licensed physicianOnline seller
PrescriptionValid patient specific prescription requiredNone
Intended for humansYes, for one identified patientThe label says no
FDA approvedNoNo
Bulk substanceFDA registered manufacturer, CGMP, certificate of analysis meeting the policy's standardSet by the seller, with no such requirement
Serious adverse eventsCompounder reports them to FDA MedWatchNo equivalent system
MoleculesSix peptides, one active ingredient per productWhatever the seller lists, including blends
FDA positionHHS does not intend to take action if all conditions are metFDA has sent warning letters treating such products as unapproved new drugs where the evidence shows human use

What changed on October 28, 2026?

HHS issued an enforcement discretion policy on 503A compounding (see our news report), followed by a notice in the Federal Register on October 30, 2026 (docket HHS-OASH-2026-0496). Until each peptide is addressed in a final rule, HHS says it does not intend to take action against a state licensed pharmacy, a federal facility or a licensed physician compounding one of six listed peptides, provided all the conditions are present.

This followed the Pharmacy Compounding Advisory Committee vote of July 2026, when the committee backed the same six peptides against the recommendation of FDA staff. HHS's own document records that FDA's drug center (CDER) recommended against listing them, and gives its reasons for including them anyway: documented historical use, new lot level testing data, and either the policy's safeguards or HHS's reading of the safety data, depending on the peptide.

The notice's background section calls the document a draft and accepts written comments. Enforcement discretion is a narrow tool. It is not a law, an approval or a listing. No peptide was added to the 503A bulks list by this policy, and the notice says the policy does not establish rights for any person and is not binding on HHS or the public.

Which peptides does the policy cover, and by which route?

The policy covers six peptides, each limited to specific forms. A compounded product outside these forms falls outside the policy.

PeptideForm coveredRoutes covered
BPC-157AcetateSubcutaneous, intramuscular, oral, topical
TB-500AcetateSubcutaneous, intramuscular
MOTS-cAcetateSubcutaneous, intramuscular
EpitalonAcetateSubcutaneous, intramuscular, in intermittent courses
SemaxFree baseIntranasal
KPVAcetateTopical, oral

For any oral form, the policy adds a specific burden: because oral absorption of peptides is difficult, the compounder is expected to keep documentation showing that the exact formulation reaches an adequate level of oral bioavailability in humans.

What conditions must a compounder meet?

All of these conditions must be present for the policy to apply:

  • Prescription: a valid patient specific prescription, as section 503A requires.
  • Listed substance and identity: the peptide appears in the policy's Appendix A and matches the identity and route limits in Appendix B.
  • Single active ingredient: one listed peptide per product. HHS explains that this makes adverse events easier to attribute to a specific substance.
  • Manufacturer: the original manufacturer is registered with FDA, complies with CGMP, and has its physical location listed on the certificate of analysis.
  • Certificate of analysis: results consistent with the criteria in Appendix B, covering identity, purity, potency and contaminants such as endotoxins, heavy metals and microbial contamination.
  • Reporting: serious adverse events and product quality issues go to FDA MedWatch, whether or not the event is considered drug related, and products compounded are reported to FDA and the relevant states.
  • Labeling: the statement "This is a compounded drug product. Not for resale." plus the procedure for reporting problems.
  • Device: the only delivery device packaged with or containing the product is an FDA 510(k) cleared syringe.
  • Other requirements: compliance with the rest of the FD&C Act, including no insanitary conditions.

What stays outside the policy?

Several things readers often assume are covered are not:

  • Retatrutide: it is not among the six, and FDA states that it cannot be used in compounding under federal law.
  • Blends: the single ingredient condition excludes combination products, such as blends of BPC-157 and TB-500 or the Klow and Glow blends.
  • Pre-filled pens: the policy allows only a 510(k) cleared syringe as the device and says more complex devices add risk, which on its face leaves out pens.
  • Other peptides: DSIP was voted down in July. GHK-Cu, Melanotan II, LL-37, Dihexa and PEG-MGF are not in Appendix A; Holland & Knight reports that a further committee meeting on them is expected by February 2027.
  • 503B outsourcing facilities: the policy addresses state licensed pharmacies, federal facilities and licensed physicians.
  • Research use only products: the policy says nothing in their favor, as the next section shows.

What does the policy mean for research use only sellers?

HHS states its aim directly: the policy "will discourage the continued, widespread use of certain research-use-only peptides supplied by foreign manufacturers that pose a safety risk to US patients", and it describes compounding as "a more controlled alternative". Nothing in the policy protects a seller who supplies the same molecule with a research use only label.

FDA enforcement against these sellers predates it. FDA issued warning letters to online peptide sellers in March and August 2026, treating products as unapproved new drugs where the evidence showed human use, whatever the label said. Details are in our guide to peptide legality.

Our own position: Klow Peptide earns affiliate commissions from research peptide vendors, and at the time of writing from no prescription program. Read this page knowing that, and check the official documents listed below.

Does compounded mean proven safe or effective?

No. The policy is about enforcement, not about evidence. HHS says compounded drugs may pose risks to patients, and FDA says compounded drugs should only be used when a patient's medical need cannot be met by an approved drug. FDA staff recommended against listing these peptides, and critics dispute the decision: RAPS reports objections from Public Citizen, for whom all peptide substances should go through the standard FDA approval process for new drugs.

A certificate of analysis on a bulk substance is useful, but it describes that lot of raw material. It does not show that a peptide works for a given condition, or that long term use is safe. For what the evidence does and does not show, see our page on whether peptides are safe.

How long will this policy last?

The notice sets no end date. The policy runs until each peptide is addressed in a final rule, and HHS may revisit it, in whole or in part, if a safety signal or product quality issue arises. Written comments can be submitted on regulations.gov for two weeks after publication, so until about November 13, 2026.

It may also be challenged or changed. Holland & Knight notes that trade groups have argued FDA cannot authorize compounding through an interim policy while rulemaking is pending, and that a future administration could reverse it quickly. The same firm expects a lasting federal pathway in 2027 or 2028. Anyone planning around this policy should treat it as temporary.

What should you check if a clinician offers a compounded peptide?

Most of these questions follow from the policy's conditions. They are not medical advice, and any decision about treatment belongs with a licensed clinician who knows your history.

  • Is this a prescription written for you after a real clinical assessment?
  • Is the pharmacy state licensed, and does it hold a license for your state?
  • Does the product contain one active ingredient, in a form and route the policy covers?
  • Who is the original manufacturer of the bulk substance, and is its location on the certificate of analysis?
  • Does the label say "This is a compounded drug product. Not for resale." and explain how to report a problem?
  • If a device comes with the product, is it a syringe, and not a pen or other complex device?
  • What monitoring is planned, and what would make the clinician stop treatment?

Several US telehealth companies have announced programs since the policy was issued. We have not assessed them on this page, and a lower price says nothing about whether these conditions are met.

Does this change anything outside the United States?

No. This is a US policy on US compounding. In the European Union, a pharmacologically active injectable peptide remains within medicines law, and other countries apply their own rules, some of them stricter. Our legal guide links to the rules by country. General information only, not legal advice.

Recommended products

Research peptides selected for quality and purity:

Test your knowledge

Quick quiz · 6 questions

Frequently Asked Questions

Is BPC-157 legal in the US now?
Not in a general sense. BPC-157 is not FDA approved. Since October 28, 2026, HHS has said it does not intend to act against a state licensed pharmacy, federal facility or licensed physician compounding BPC-157 acetate when all the policy's conditions are met, including a valid patient specific prescription. The policy does not cover research use only products.
Did the FDA approve these six peptides?
No. HHS issued an enforcement discretion policy, which is a statement about when it does not intend to act. HHS states that compounded drugs are not FDA approved. FDA's drug center recommended against listing the six peptides, and no final rule has added them to the 503A bulks list.
Can I get compounded retatrutide?
Retatrutide is not covered by the policy, and FDA states that it cannot be used in compounding under federal law. It is an investigational drug that is not approved for sale in the United States.
Are compounded peptide pens covered?
The policy says the only delivery device packaged with or containing the compounded drug is an FDA 510(k) cleared syringe, and that more complex devices add risk. On its face, that leaves out pre-filled pens.
Does the policy make research use only peptides legal?
No. The policy covers compounding only, and HHS says it is meant to discourage the use of research use only peptides supplied by foreign manufacturers. FDA has sent warning letters treating such products as unapproved new drugs where the evidence shows human use.
Does this apply in Europe?
No. It is a US policy. EU medicines law and other national rules continue to apply. See our guide on whether peptides are legal for the rules by country.

Sources

  1. U.S. Department of Health and Human Services (2026). HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendices A and B. HHS. (hhs.gov)
  2. U.S. Department of Health and Human Services (2026). Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, notice of availability, docket HHS-OASH-2026-0496. Federal Register, 91 FR 68526. (federalregister.gov)
  3. U.S. Food and Drug Administration (2026). Human Drug Compounding. FDA. (fda.gov)
  4. U.S. Food and Drug Administration (2026). FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. FDA. (fda.gov)
  5. Regulatory Affairs Professionals Society (2026). HHS will permit compounding of six peptides ahead of formal rulemaking. RAPS. (raps.org)
  6. Holland & Knight (2026). Peptides at a Crossroads: What Wellness Providers Need to Know About HHS and FDA Actions. Holland & Knight. (hklaw.com)

This content is for informational and educational purposes only. It does not constitute medical advice. Consult a healthcare professional before making any decisions. Read our full medical disclaimer